

EMPLICURE RECEIVES FORMAL NOTIFICATION OF APPROVED US PATENT FOR INHALATION OF PHARMACEUTICALS

Emplicure AB has received issue notification from the US Patent and Trademark Office that a formal approval of the inhalation platform of pharmaceuticals will be issued on December 21, 2021.

”The United States is an important market for us. The announcement of patent approval for inhaled drugs is extremely gratifying and important, as it strengthens our conditions to develop new unique and patent-protected pharmaceutical products for inhalation”, says Torbjörn W. Larsson, CEO of Emplicure

The patent, U.S. Patent No. 11,202,871 will be valid into 2037. The information about the preliminary approval was published August 19, 2021.

Adviser

Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

For more information, please contact:

Torbjörn W. Larsson

CEO

Phone: +46 (0)70 747 65 99

Email: twl@emplicure.com

Anna-Lena Nicolson

CFO, Investor Relations

Phone: +46 (0)72 33 68 68

Email: aln@emplicure.com



Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at www.emplicure.com